TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from LadRx (LADX).
On June 3, 2024, LadRx Corporation ended its exclusive worldwide license agreement for aldoxorubicin with NantCell, clearing all obligations except potential negotiations for LadRx to buy remaining aldoxorubicin inventory. Concurrently, LadRx amended its royalty agreement with XOMA, outlining new royalty payments if LadRx commercializes aldoxorubicin itself or licenses it to a third party. These strategic moves could reshape LadRx’s future revenue streams and impact investor outlook on the company’s market position.
Learn more about LADX stock on TipRanks’ Stock Analysis page.